Predicting erenumab adverse events with single-cell genomics

Lancet. 2020 Jul 11;396(10244):95-96. doi: 10.1016/S0140-6736(19)32952-6.

Authors

Angeliki Vgontzas¹, William Renthal²

Affiliations

¹ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
² Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: wrenthal@bwh.harvard.edu.

PMID: 32653068
DOI: 10.1016/S0140-6736(19)32952-6

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Calcitonin Gene-Related Peptide Receptor Antagonists / adverse effects*
Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use
Clinical Decision Rules
Clinical Trials as Topic
Constipation / chemically induced
Genomics / methods*
Hospitalization / statistics & numerical data
Humans
Mice
Migraine Disorders / drug therapy
Peripheral Nervous System / cytology
Peripheral Nervous System / metabolism
Placebos / administration & dosage
Receptors, Calcitonin Gene-Related Peptide / genetics*

Substances

Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
Placebos
Receptors, Calcitonin Gene-Related Peptide
erenumab